Adoptive cell therapies in thoracic malignancies: a comprehensive review

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Thoracic malignancies, including lung cancer and mesothelioma, have limited treatment options.
• Adoptive cell therapies are emerging as a potential new modality.
• Checkpoint inhibition has shown success but is not universally effective.

Purpose of the Study:

• To review recent findings on adoptive cell therapies for thoracic cancers.
• To discuss the potential and challenges of implementing these therapies.
• To highlight ongoing developments in cellular therapy for lung cancer and mesothelioma.

Main Methods:

• Literature review of recent studies on adoptive cell therapies.
• Analysis of ongoing clinical trials and reported results.
• Discussion of implementation challenges, including toxicity and cost.

Main Results:

• Adoptive cell therapies, such as tumor-infiltrating lymphocytes and CAR T cells, are being investigated for thoracic malignancies.
• Early results suggest potential efficacy, particularly in patients refractory to checkpoint inhibitors.
• New toxicity profiles and financial burdens associated with these therapies are noted.

Conclusions:

• Adoptive cell therapies represent a promising avenue for treating thoracic malignancies.
• Further research is needed to optimize antigen identification, efficacy, and safety.
• Significant advancements are being made in developing cellular therapies for lung cancer and mesothelioma.